NCT00293124 - Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors | Biotech Hunter

Enrollment

125

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2008

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG

Glivec

400mg p.o./day in a population of patients with locally advanced (=not amenable to surgery with curative intent) or metastatic malignant GIST. Glivec® may be increased to 600 mg p.o./day and then 800 mg p.o./day (400 mg b.i.d.) if the patient is progressing

Trial Locations (16)

1090

AKH, Universitätsklinik für Innere Medizin 1, Vienna

1527

SBALO National Oncology Center, Sofia

400015

Institutul Oncologic Cluj, Cluj-Napoca

Unknown

Institute of Oncology Sarajevo, Sarajevo

National Oncological Center Hospital, Sofia

Sofia Cancer Center compl. Mladost ,, Sofia

Clinical Hospital Split, Center of Oncology, Split

University Hospital Rebro, Zagreb

Radioterapeticko-onkologicke. Oddeleni FN Motol, Prague

Lithuanian Oncology Center,, Vilnius

Institutul Oncologic Bucuresti, Bucharest

Emergency Clinical County Hospital , Clin Oncol. Dep, Craiova

Institut za onkologiju i, Belgrade

National Institute of Oncology, Bratislava

Oncology Institute Ljubljana, Ljubljana

186 00

FN Bulovka, Prague

All Listed Sponsors

lead

Central European Cooperative Oncology Group

OTHER